German molecular diagnostics startup GNA Biosolutions has received Emergency Use Authorization (Sonderzulassung) from the German Federal Institute for Drugs and Medical Devices (BfArM) for the GNA Octea SARS-CoV-2 Test System. The new technology developed by GNA Biosolutions enables decentralized COVID-19 rapid tests in approximately 40 minutes without sacrificing sensitivity.